Protein Science, Vol 3, Issue 10 1687-1696, Copyright © 1994 by Cold Spring Harbor Laboratory Press

INVITED PAPER, SPECIAL SECTION IN HONOR OF MAX PERUTZ

Influenza virus neuraminidase: Structure, antibodies, and inhibitors

P. M. COLMAN
Biomolecular Research Institute, 343 Royal Parade, Parkville, Victoria, Australia 3052

The determination of the 3-dimensional structure of the influenza virus neuraminidase in 1983 has served as a platform for understanding interactions between antibodies and protein antigens, for investigating antigenic variation in influenza viruses, and for devising new inhibitors of the enzyme. That work is reviewed here, together with more recent developments that have resulted in one of the inhibitors entering clinical trials as an anti-influenza virus drug.
CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				C.-J. Wei, L. Xu, W.-P. Kong, W. Shi, K. Canis, J. Stevens, Z.-Y. Yang, A. Dell, S. M. Haslam, I. A. Wilson, et al. Comparative Efficacy of Neutralizing Antibodies Elicited by Recombinant Hemagglutinin Proteins from Avian H5N1 Influenza Virus J. Virol., July 1, 2008; 82(13): 6200 - 6208. [Abstract] [Full Text] [PDF]

				H.-L. Yen, E. Hoffmann, G. Taylor, C. Scholtissek, A. S. Monto, R. G. Webster, and E. A. Govorkova Importance of neuraminidase active-site residues to the neuraminidase inhibitor resistance of influenza viruses. J. Virol., September 1, 2006; 80(17): 8787 - 8795. [Abstract] [Full Text] [PDF]

				A. C. Hurt, P. Iannello, K. Jachno, N. Komadina, A. W. Hampson, I. G. Barr, and J. L. McKimm-Breschkin Neuraminidase inhibitor-resistant and -sensitive influenza B viruses isolated from an untreated human patient. Antimicrob. Agents Chemother., May 1, 2006; 50(5): 1872 - 1874. [Abstract] [Full Text] [PDF]

				H.-L. Yen, L. M. Herlocher, E. Hoffmann, M. N. Matrosovich, A. S. Monto, R. G. Webster, and E. A. Govorkova Neuraminidase Inhibitor-Resistant Influenza Viruses May Differ Substantially in Fitness and Transmissibility Antimicrob. Agents Chemother., October 1, 2005; 49(10): 4075 - 4084. [Abstract] [Full Text] [PDF]

				A. Desogus, R. Burioni, A. Ingianni, F. Bugli, R. Pompei, and G. Fadda Production and Characterization of a Human Recombinant Monoclonal Fab Fragment Specific for Influenza A Viruses Clin. Vaccine Immunol., July 1, 2003; 10(4): 680 - 685. [Abstract] [Full Text] [PDF]

				L. V. Gubareva, M. S. Nedyalkova, D. V. Novikov, K. G. Murti, E. Hoffmann, and F. G. Hayden A release-competent influenza A virus mutant lacking the coding capacity for the neuraminidase active site J. Gen. Virol., November 1, 2002; 83(11): 2683 - 2692. [Abstract] [Full Text] [PDF]

				M. Porotto, O. Greengard, N. Poltoratskaia, M.-A. Horga, and A. Moscona Human Parainfluenza Virus Type 3 HN-Receptor Interaction: Effect of 4-Guanidino-Neu5Ac2en on a Neuraminidase-Deficient Variant J. Virol., August 15, 2001; 75(16): 7481 - 7488. [Abstract] [Full Text] [PDF]

				F. G. Hayden, J. J. Treanor, R. S. Fritz, M. Lobo, R. F. Betts, M. Miller, N. Kinnersley, R. G. Mills, P. Ward, and S. E. Straus Use of the Oral Neuraminidase Inhibitor Oseltamivir in Experimental Human Influenza: Randomized Controlled Trials for Prevention and Treatment JAMA, October 6, 1999; 282(13): 1240 - 1246. [Abstract] [Full Text] [PDF]

				D. P. Calfee, A. W. Peng, L. M. Cass, M. Lobo, and F. G. Hayden Safety and Efficacy of Intravenous Zanamivir in Preventing Experimental Human Influenza A Virus Infection Antimicrob. Agents Chemother., July 1, 1999; 43(7): 1616 - 1620. [Abstract] [Full Text]

				C. Y. Tai, P. A. Escarpe, R. W. Sidwell, M. A. Williams, W. Lew, H. Wu, C. U. Kim, and D. B. Mendel Characterization of Human Influenza Virus Variants Selected In Vitro in the Presence of the Neuraminidase Inhibitor GS 4071 Antimicrob. Agents Chemother., December 1, 1998; 42(12): 3234 - 3241. [Abstract] [Full Text]

				S. Bantia, A. A. Ghate, S. L. Ananth, Y. S. Babu, G. M. Air, and G. M. Walsh Generation and Characterization of a Mutant of Influenza A Virus Selected with the Neuraminidase Inhibitor BCX-140 Antimicrob. Agents Chemother., April 1, 1998; 42(4): 801 - 807. [Abstract] [Full Text]

				J. N. Varghese, P. M. Colman, A. van Donkelaar, T. J. Blick, A. Sahasrabudhe, and J. L. McKimm-Breschkin Structural evidence for a second sialic acid binding site in avian influenza virus neuraminidases PNAS, October 28, 1997; 94(22): 11808 - 11812. [Abstract] [Full Text] [PDF]

				E Bonten, A van der Spoel, M Fornerod, G Grosveld, and A d'Azzo Characterization of human lysosomal neuraminidase defines the molecular basis of the metabolic storage disorder sialidosis. Genes & Dev., December 15, 1996; 10(24): 3156 - 3169. [Abstract] [PDF]